Iron addiction: A novel therapeutic target in ovarian cancer

Oncogene

Volumn 36, Issue 29, 2017, Pages 4089-4099

  Basuli, D ^a   Tesfay, L ^a   Deng, Z ^a   Paul, B ^a   Yamamoto, Y ^b   Ning, G ^c   Xian, W ^d   McKeon, F ^e   Lynch, M ^a   Crum, C P ^f   Hegde, P ^a   Brewer, M ^a   Wang, X ^a   Miller, L D ^g   Dyment, N ^a   Torti, F M ^a   Torti, S V ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c JACKSON LABORATORY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e University of Houston   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD71 ANTIGEN; ERASTIN; FERRITIN; FERROPORTIN; INTERLEUKIN 6; IRON; IRON CHELATING AGENT; IRON REGULATORY PROTEIN 2; MATRIX METALLOPROTEINASE; MESSENGER RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER INHIBITION; CARCINOGENICITY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FERROPTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IRON METABOLISM; IRON TRANSPORT; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; TUMOR CELL; TUMOR INVASION; TUMOR VOLUME; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PATHOLOGY;

ANIMALS; FEMALE; HUMANS; IRON; MICE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS;

EID: 85015710412     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.11     Document Type: Article

References (48)

1. A snapshot of ovarian cancer. National Cancer Institute. Available from http://www.cancer.gov/research/progress/snapshots/ovarian (accessed 21 December 2015).
2. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-282.
3. Leong HS, Galletta L, Etemadmoghadam D, George J, Kobel M, Ramus SJ et al. Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol 2015; 236: 272-277.
4. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
5. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053-1064.
6. Landen Jr CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010; 9: 3186-3199.
7. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001.
8. Karst AM, Drapkin R. Ovarian cancer pathogenesis: A model in evolution. J Oncol 2010; 2010: 932371.
9. Ng A, Barker N. Ovary and fimbrial stem cells: Biology, niche and cancer origins. Nat Rev Mol Cell Biol 2015; 16: 625-638.
10. Yamamoto Y, Ning G, Howitt BE, Mehra K, Wu L, Wang X et al. In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells. J Pathol 2016; 238: 519-530.
11. Torti SV, Torti FM. Iron and cancer: More ore to be mined. Nat Rev Cancer 2013; 13: 342-355.
12. Torti SV, Torti FM. Ironing out cancer. Cancer Res 2011; 71: 1511-1514.
13. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003; 3: 285-296.
14. Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J et al. Advances in serous tubal intraepithelial carcinoma: Correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol 2014; 7: 848-857.
15. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 2013; 24(Suppl 10): X16-x21.
16. Dietl J. Revisiting the pathogenesis of ovarian cancer: The central role of the fallopian tube. Arch Gynecol Obstet 2014; 289: 241-246.
17. Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L et al. IRP2 regulates breast tumor growth. Cancer Res 2014; 74: 497-507.
18. Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book 2013; e195-e199.
19. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516.
20. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28: 209-218.
21. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27: 2059-2068.
22. Ning G, Bijron JG, Yamamoto Y, Wang X, Howitt BE, Herfs M et al. The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. J Pathol 2014; 234: 478-487.
23. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990; 38: 340-342.
24. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56.
25. Manz DH, Blanchette N, Paul B, Torti FM, Torti SV. Iron and Cancer: Recent insights. Ann NY Acad Sci 2016; 1368: 149-161.
26. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat commun 2013; 4: 2126.
27. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 2005; 105: 4096-4102.
28. Liu XB, Yang F, Haile DJ. Functional consequences of ferroportin 1 mutations. Blood cells mol dis 2005; 35: 33-46.
29. Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 2009; 9: 415-428.
30. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V. Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17: 6083-6096.
31. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-1072.
32. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014; 10: 9-17.
33. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 2011; 108: 7547-7552.
34. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011; 71: 6728-6737.
35. Pinnix ZK, Miller LD, Wang W, D'Agostino Jr R, Kute T, Willingham MC et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010; 2: 43ra56.
36. Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS et al. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 2015; 28: 441-455.
37. Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res 2015; 75: 2254-2263.
38. Dijkgraaf EM, Welters MJ, Nortier JW, van der Burg SH, Kroep JR. Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 2012; 18: 3816-3827.
39. Zou M, Zhang X, Xu C. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells. Cell Oncol (Dordr) 2015.
40. Lui GY, Kovacevic Z, V Menezes S, Kalinowski DS, Merlot AM, Sahni S et al. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: Inhibition of constitutive and interleukin 6-induced activation by iron depletion. Mol Pharmacol 2015; 87: 543-560.
41. Dai J, Huang C, Wu J, Yang C, Frenkel K, Huang X. Iron-induced interleukin-6 gene expression: Possible mediation through the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. Toxicology 2004; 203: 199-209.
42. Reed JC, Pellecchia M. Ironing out cell death mechanisms. Cell 2012; 149: 963-965.
43. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156: 317-331.
44. Yang WS, Stockwell BR. Ferroptosis: Death by lipid peroxidation. Trends Cell Biol 2015; 26: 165-176.
45. Shah MM, Landen CN. Ovarian cancer stem cells: Are they real and why are they important? Gynecol Oncol 2014; 132: 483-489.
46. Deng Z, Wan M, Sui G. PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol cell biol 2007; 27: 3780-3792.
47. Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell metab 2012; 15: 905-917.
48. Nguyen DH, Zhou T, Shu J, Mao J. Quantifying chromogen intensity in immunohistochemistry via reciprocal intensity. CancerInCytes 2013; 2: 1-3e.